Albany Molecular Research, Inc.  

(Public, NASDAQ:AMRI)   Watch this stock  
Find more results for Sanofi US Services Inc
17.77
+0.57 (3.31%)
Mar 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 17.24 - 17.99
52 week 13.73 - 23.95
Open 17.34
Vol / Avg. 400,520.00/427,521.00
Mkt cap 562.15M
P/E     -
Div/yield     -
EPS -0.11
Shares 32.61M
Beta 1.73
Inst. own 95%
May 4, 2015
Q1 2015 Albany Molecular Research Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 11, 2015
Albany Molecular Research Inc at Barclays Healthcare Conference - 2:50PM EDT - Add to calendar
Feb 12, 2015
Q4 2014 Albany Molecular Research Inc Earnings Release
Feb 12, 2015
Q4 2014 Albany Molecular Research Inc Earnings Call
Jan 13, 2015
Albany Molecular Research Inc at JPMorgan Healthcare Conference
Jan 9, 2015
Albany Molecular Research Inc Conference Call to Acquire Aptuit Drug Product Development and Aseptic Clinical Manufacturing Businesses
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -2.15% -1.19%
Operating margin 3.36% 2.07%
EBITD margin - 12.37%
Return on average assets - -
Return on average equity - -
Employees 1,282 -
CDP Score - -

Address

21 CORPORATE CIRCLE, P O Box 15098
ALBANY, NY 12203-5154
United States - Map
+1-518-4640279 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Albany Molecular Research, Inc. (AMRI) is a contract research and manufacturing company. The Company provides customers with fully integrated drug discovery, development and manufacturing services. The Company operates in two segments: Large Scale Manufacturing (LSM), whose activities include pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates, sterile syringe and vial filling, and high potency and controlled substance manufacturing; and Discovery, Drug Development and Small Scale Manufacturing (DDS), whose activities include pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates, sterile syringe and vial filling, and high potency and controlled substance manufacturing. The DDS segment includes activities such as drug lead discovery, optimization, drug development and small-scale commercial manufacturing.

Officers and directors

William S. Marth President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Felicia I Ladin Chief Financial Officer, Senior Vice President, Treasurer
Age: 43
Bio & Compensation  - Reuters
George Svokos Senior Vice President - Sales, General Manager - API
Age: 56
Bio & Compensation  - Reuters
Christopher Conway Senior Vice President - Global Sales and Marketing
Bio & Compensation  - Reuters
Milton Boyer Senior Vice President - Drug Product Manufacturing
Bio & Compensation  - Reuters
Steven R. Hagen Ph.D. Senior Vice President - Manufacturing and Pharmaceuticals
Age: 53
Bio & Compensation  - Reuters
Michael A. Luther Ph.D. Senior Vice President - Discovery Services
Age: 58
Bio & Compensation  - Reuters
Jimmy Wang Ph.D. Chief Information Officer
Bio & Compensation  - Reuters
Lori M. Henderson Esq. Vice President, General Counsel, Secretary
Age: 52
Bio & Compensation  - Reuters
Thomas E. D' Ambra Ph.D. Non-Executive Chairman of the Board
Age: 58
Bio & Compensation  - Reuters